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1.INTRODUCTION 
DOSAGE FORMS 
THE NEED FOR DOSAGE FORMS 
[1] 
The potent nature and low dosage of most of the drugs in use today precludes any 
expectation that the general public could safely obtain the appropriate does of drug from the 
bulk material. Most drug substances are administered in milligram quantities, much too small 
to be weighed on anything but a sensitive prescription or electronic analytical balance. 
When the dose of the drug is minute, solid dosage forms such as tablets and capsules 
must be prepared with fillers or diluents so that the dosage unit is large enough to pick up 
with the fingertips. 
Besides providing the mechanism for the safe and convenient delivery of accurate 
dosage, dosage forms are needed for additional reasons. 
 To protect the drug substance from the destructive influences of atmospheric 
oxygen or humidity (coated tablets, sealed ampoules) 
 To protect the drug substance from the destructive influence of gastric acid after 
oral administration (enteric-coated tablets). 
 To conceal the bitter, salty, or offensive taste or odor of a drug substance(capsules, 
coated tablets ,flavored syrups) 
 To provide liquid preparations of substances that are either insoluble or unstable in 
the desired vehicle (suspensions) 
 To provide clear liquid dosage forms of substances (syrups, solutions) 
 To provide rate-controlled drug action (various controlled-release tablets, capsules 
and suspensions) 
 To provide optimal drug action from topical administration sites (ointments, 
creams, transdermal patches and ophthalmic, ear and nasal preparations) 
 To provide for insertion of a drug into one of the body’s orifices(rectal or vaginal 
suppositories) 
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 To provide for placement of placement of drugs directly in the bloodstream or 
body tissues (injections) 
 To provide for optimal drug action through inhalation therapy (inhalants and 
inhalation aerosols) 
GENERAL CONSIDERATIONS IN DOSAGE FROM DESIGN 
     Before formulating a drug substance into a dosage from, the desired product type must be 
determined as far as possible to establish the framework for product development. The 
formulation that best meets the goals for the product is selected to be its master formula. 
Each batch of product subsequently prepared must meet the specifications established in the 
master formula. 
     These liquids, which are flavored aqueous solutions, syrups or suspensions are usually 
administered directly into the infant’s or child’s mouth by drop, spoon or oral dispenser or 
incorporated into the child’s food. A single liquid pediatric preparation may be used for 
infants and children of all ages, with the dose of the drug varied by the volume administered. 
Infant-size rectal suppositories may also be employed, although drug absorption from the 
rectum is often erratic. 
     Some medications are formulated as chewable tablets. Newly available tablets dissolve in 
the mouth in about 10 to 15 seconds. This allows the patient to take a tablet but actually 
swallow a liquid. 
      Medications intended for the elderly are commonly formulated into oral liquid or may be 
extemporaneously prepared into an oral liquid by the pharmacist. 
Types of dosage forms:
 [2]
 
 There are different forms into which a drug may be placed (regulated/given or taken) 
for convenient and effective treatment of disease. Drugs can be prepared for administration 
by very conceivable route and the suitable preparation is formulated to insure maximum 
therapeutic response. These may be tablets, capsules, solutions, syrups, elixirs, suspensions, 
gels, powders, troches or lozenge , ointments, creams, pastes, aerosol, lotions, sprays, 
inhalants, emulsions and suppositories .The preferred dosage forms in different routes of 
administration is listed. 
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Table No.1 Types of dosage form 
S.No TERM SITE 
1 Oral 
Tablets, Capsules, Solutions Syrups, Elixirs, Suspensions 
Gels, Powders. 
2 Sublingual Tablets Troches or  Lozenge 
3 Parenteral Solutions Suspensions 
4 Epicutaneous Solutions, Suspensions Gels, Powders Ointments, Sprays. 
5 Conjunctival Ointments and Solutions 
6 Intraocular Solutions and Suspensions 
7 Intranasal Solutions, Ointments Aersol, Sprays Inhalants 
8 Intrarespiratory Aerosol 
9. Rectal Solutions, Ointments Suppositories 
10 Vaginal Tablets,  Solutions, Ointments, Emulsions and Suppositories 
11 Urethral Solutions and Suppositories 
Advantages and Disadvantages of oral route of administration: Drugs are usually taken by 
oral route of administration. The advantages and disadvantage of oral route of administration 
are discussed below: 
Advantages of oral route of administration:
 [3]
 
1. It is most easy route for administration of drug for patients. 
2. It is the safest route of administration. 
3. It is most convenient for patients. 
4. This route can be used for large variety of dosage forms. 
5. Nursing for administration is not required. 
6. An allergic reaction of drug (toxicity) is delayed and hence safe. 
7. It is economical to the patients. 
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Disadvantages of oral route of administration:
 
 
      1. The onset of action of drug is late and hence recovery is not fast. Therefore oral route 
of administration is not preferred in emergency. 
      2. As it is absorbed form gastrointestinal tract the dose of drug required is more. 
      3. It is difficult route of administration of drug for non-cooperative patients like babies 
and children. 
      4. It is difficult route of administration of drug for unconscious patients. 
      5. The absorption of drug from gastrointestinal tract is not assured by patients suffering 
from gastrointestinal disorder. 
     6. Oral route of administration may cause gastrointestinal disorders like acidity, loss of 
appetite, etc. 
     7. The uncertainty of maintenance of the dose of drug is possible in oral route of 
administration. 
     8. Drug may be destroyed or inactivated by the enzyme in gastrointestinal tract. 
LIQUID DOSAGE FORMS
[4]
 
INTRODUCTION: 
     Solution is a homogenous one-phase system consisting of two or more components. The 
solvent, or mixture of solvents, is the phase in which the dispersion occurs, and the 
component which is dispersed as molecules or ions in the solvent. 
     For most pharmaceutical solutions, the solvent system is likely to be liquid, and the solute 
will be either a liquid or a solid. Solid dispersions, in which both solute and solvent are solids, 
are used for the improvement of the bioavailability of poorly soluble drugs.        The solute is 
present as a molecular dispersion and will therefore exhibit a fast rate of dissolution, owing 
to its very high specific surface area. In addition, the particles are already in a disaggregated 
and wetted state, and so there is little air adsorbed on the particle surface to inhibit 
dissolution. There may even be slight increases in actual solubility. 
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Solutions are used in many ways; they are- 
a) Taken orally—as mixtures, elixirs, linctuses, draughts, syrups and paediatric drops. 
b) Used in the mouth and throat- as mouthwashes, gargles, throat paints and throat 
sprays. 
c) Instilled into body cavities- as douches, enemas, ear drops, nasal drops nasal sprays. 
d) Applied to body surfaces- as collodions, liniments, lotions and paints. 
     Solutions may be prepared from any combination of solid, liquid and gas, the three states 
of matter. Solutions are liquid preparations that contain one or more chemical substances 
dissolved in a suitable solvent or mixture of mutually miscible solvents. 
     Oral solutions, syrups, elixirs, spirits and tinctures are prepared and used for the specific 
effects of the medicinal agents they carry. In these preparations, the medicinal agents are 
intended to provide systemic effects. The fact that they are administered in solution form 
usually means that they are soluble in aqueous systems and that their absorption from the 
gastrointestinal tract into the systemic circulation may be expected to occur more rapidly 
than from suspension or solid dosage forms of the same medicinal agent. 
     Solutes other than the medicinal agents are usually present in orally administered 
solutions. These additional agents usually are included to provide color, flavor, sweetness, or 
stability.  
Advantage of Liquid dosage forms:
 
 
 Effective more quickly than a solid dosage because drug is already dissolved in a 
liquid. 
 Easier to swallow than solid dosage form for many patients. 
 Drugs may be available only in liquid form owing to convenience of administration. 
 Uniformity and flexibility of dosage form. 
 Certain medications may cause gastrointestinal distress if administered in a solid 
dosage form. 
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Disadvantages of Liquid dosage forms:
 
 
 Deterioration and loss of potency occur more quickly than solid dosage form. 
 Incompatibilities of dissolved substances. 
 May require preservatives to prevent bacteria or mold from developing. 
 Inaccurate measuring of a dose for patient may occur. 
 Interactions may develop from changes in solubility. 
 Bulkier and inconvenient to carry than solid dosage forms. 
                                                                  SYRUPS
[5]
 
Syrups are concentrated, aqueous preparations of a sugar or sugar-substitute with or without 
added flavoring agents and medicinal substances. Syrups containing flavoring agents but not 
medicinal substances are called flavored vehicles (syrups).e.g. Cherry Syrup, Cocoa Syrup, 
Orange syrup, Raspberry Syrup. Syrups containing medicinal agents are called medicated 
syrups. e.g. Chlorpheniramine maleate syrup, Ipecac syrup, Chloral hydrate syrup etc. 
Components of syrups:
 
 
Most syrups contain the following components in addition to the purified water and 
any medicinal agents present: 
1. The sugar, usually sucrose, or sugar substitutes used to provide sweetness and 
viscosity, 
2. Antimicrobial preservatives, Flavorants, and Colorants. 
Sucrose and non-sucrose based syrup:
 
 
Sucrose is most frequently employed in syrups. In special circumstances it may be 
replaced by sugars, such as, dextrose, or non-sugars as sorbitol, glycerin and propylene 
glycol. 
Methyl cellulose or hydroxyethyl cellulose -these two materials are not hydrolyzed 
and absorbed into the blood stream and their use results in an excellent syrup-like vehicle. 
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Taste masking by syrup:
 
 
The syrup imparts a characteristics “body” (viscosity) and together with the 
sweetness and the flavorants results in a type of pharmaceutical preparation that is quite 
effective in masking the taste of added medicinal agents. When the syrup is swallowed, only 
a portion of dissolved drug actually makes contact with the taste buds, the remainder of the 
drug being carried past them and down the throat in the containment of the viscous syrup. In 
the case of antitussive syrups (e.g. linctus) the thick sweet syrup has a soothing effect on the 
irritated tissues of the throat as it passes over them. 
Preparation of Syrups:
 
 
Syrups are frequently prepared by one of four general methods. depending upon the 
physical and chemical characteristics of the ingredients.  
1.  Solution of the ingredients with the aid of heat  
2.  Solution of the ingredients by agitation without the use of heat 
3. Addition of sucrose to a prepared medicated liquid or to a flavored liquid and 
4. By percolation of either the source of the medicating substance or of the sucrose. 
Solution with the aid of heat:  
The sugar is generally added to the purified water, and heat is applied until solution is 
effected. Then other required heat-stable components are added to the hot syrup, the mixture 
is allowed to cool, and its volume is adjusted to the proper level by the addition of purified 
water. The use of heat facilitates the rapid solution of the sugar as well as certain other 
components of syrups. If excessive heating occurs then sucrose may be hydrolyzed into 
dextrose (D-glucose), and fructose (levulose). This hydrolytic reaction is referred to as 
inversion, and the combination of the two monosaccharides is invert sugar.  
When heat is applied in the preparation of sucrose syrup, some inversion of the 
sucrose is almost certain. The speed of inversion is greatly increased by the presence of acids, 
the hydrogen ion acting as a catalyst to reaction. Invert sugar is sweeter than sucrose, and 
normally colorless. Syrup darkens due to the effect of heat on the fructose. When the syrup is 
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greatly overheated, it becomes amber colored due to the caramelization of the sucrose. 
Syrups so decomposed are more susceptible to fermentation and microbial growth. Because 
of the prospect of decomposition by heat, syrups cannot be sterilized by autoclaving.  
Solution by agitation without heat:
 
 
Sucrose and other formulation agents may be dissolved in purified water by placing 
the ingredients in a vessel of greater capacity than the volume of syrup to be prepared, thus 
permitting the thorough agitation of the mixture. 
Advantage of syrups:
 
 
 The active agent is homogeneously dispersed through the product. 
 The active agent is in solution and does not need to undergo dissolution ; therefore , 
the therapeutic response is generally faster than if a tablet or capsule dosage from is 
used for treatement. 
 The dose of the active agent is easily and conveniently adjusted by measuring a 
different volume. 
 Syrups may be swallowed by patients who have difficulty taking tablets or capsules, 
as might be thease with pediatric or geriatric patients. 
 Drugs such as potassiumchloride that may casue ulceration to the mucosa in a tablet 
formulation avoid this side effect when present in solution. 
Disadvantage of syrups:
 
 
 The active ingredients, when present in solution, are usually more susceptible to 
chemical degradation, particualry hydrolysis, than when they are in solid dosage 
form. 
 As a consequence of this, the soultion product has a shorter shelf life than the soild 
formulation. 
 Some pharmacologic agents taste or smell bad enough in solution that the patient has 
difficulty taking the medication. 
 Liquid dosage forms are heavier and take up more shelf space than corresponding 
soild dosage sorms. If the container breaks, the porduct is irretrievably lost. 
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 Liquid dosage forms may require special storage facilities in very cold or very hot 
conditions. One example of this involves taking, medicine , such as an antibiotic 
suspension , on a lengthy trip. In one case the drug might need to be kept refrigerated, 
and in another case the patient may need to protect the drug from freezing. 
 The delivery of the dose depends upon the patient , or care-giver , measuring the 
proper volume.This can be a significant issue for vision-impaired patients , patients 
with arthritis,  or patients unable to read the numbers on an oral dosing syringe or 
medicine cup. 
 Liquid preparation are often susceptiable to microorganisms, and therefore 
preservatives are frequently incorporated into the formulation .Some patients may be 
allergic to certain preservatives. 
TASTE MASKING 
          Swallowing tablets is a problem for many patients particularly for children and 
geriatric patients especially when the tablets are large. Certain medicaments have an 
unpleasant taste in the throat when they are orally administrated. So some agents are added 
disclosed which when incorporated in the composition mask these bitter taste .The 
conventional oral dosage forms possess sustained release anti-tussive characteristics. 
 Microcapsules are formulated into chewable taste masked oral tablets or capsules that 
provide for immediate rapid release in the stomach. The meth acrylic acid copolymer can be 
a copolymer of polymethacrylic acid and acrylic acid esters. These polymers coating should 
be used for immediate release characteristics in microcapsule techniques. 
 Many drugs containing amine or amide groups or salts there of often have a strong 
bitter taste. Taste masking techniques using various sweeteners, amino acids, flavors & 
adsorbents have been unsuccessful in masking the taste. Most coating techniques don’t have 
an acceptable in-vivo drug releasing mechanism cation exchange resins have been used to 
adsorb amine drugs for sustained release action & taste masking. The widely used cat ion- 
exchange resins are poly sulfonic acid & poly carboxylic acid polymers. 
 A variety of  delivery systems are being developed for different routes of 
administrations like oral, parenteral, nasal & transdermal, The oral route remains attractive 
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for drug delivery because this mode of administration is an easy, convenient, noninvasive & 
familiar method of drug delivery . 
 The common oral dosage forms include liquid mixtures, tablets, capsules & liquid 
filled capsules. The solid dosage forms are futher modified depending on the therapeutic 
action desired like controlled, extended, or delayed release. 
 Patients at the extremes of age, such as children and the elderly often experienced 
difficulty in swallowing solid dosage forms. Liquid dosage forms such as solution, emulsions 
& suspensions. Usually lead to perceptible exposure of the active drug ingredient to the taste 
buds, which is a very serious problem when the drug has an extremely unpleasant taste. 
 Conventional taste masking techniques such as sweeteners, amino acids, flavoring 
agent are often unsuccessful in masking the taste of the highly bitter drugs like quinine, 
ofloxacin & clarithromycin etc. 
 Taste masking is a major problem when the drugs are extremely unpleasant. This 
problem is not restricted to the liquid oral composition like solution, dry syrup & suspensions 
but may also be encountered during the formulation of chewable tablets where in these 
dosage forms usually lead to perceptible exposure of active ingredient to taste buds. 
Depending on the type of dosage form various methods have been employed to overcome the 
unpleasant taste and bitterness of the drug. 
 Various method for taste masking have been tried earlier which include use of ion 
exchange resins, complexation of bitter drugs with pharmaceutically acceptable recipients 
and coating of drugs by lipids using a various polymeric materials. Coating of the active 
ingredient can be done by any of the techniques known in the art like microencapsulation. 
 The use of ion exchange resins to adsorb drugs containing amino  groups for  taste 
masking has found limited applicability in masking the taste of highly bitter drugs, and also 
where the drugs is to be dispersed in a liquid oral  composition for long duration of time. 
 Another technique is mouth disintegrating tablet. In this method, The tablet 
disintegrate in oral cavity with saliva in 15 sec to 60 sec, without need of water and should 
have pleasant mouth feel. 
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These task masking formulations frequently are flavored with fruit or mint flavors, 
usually for purposes of masking an unpleasant taste caused by the presence of a dissolved or 
suspended pharmacologically active substance. A pleasant taste is particularly important 
when the formulation is intended for ingestion by children. The typical flavors which are 
commonly used in formulations. They are grape, cirus, peach, strawberry, peppermint and 
many other flavors.  
TECHNIQUES EMPLOYED FOR TASTE MASKING 
  The methods commonly employed for achieving effective taste masking 
include various physical and chemical methods that prevent the drug substance from 
interaction with the taste buds. 
A) Use of Flavor Enhancers 
  The materials for taste masking purpose have often been classified depending 
upon the basic taste that is masked. Flavoring and perfuming agents can be obtained from 
either natural or synthetic sources. Natural products include fruit juices, synthetic products 
like aromatic oils such as peppermint oil and lemon oil, herbs, spices and distilled fractions. 
They are available as concentrated extracts, alcoholic or aqueous solutions, syrups or spirit.
 
Apart from these conventional materials many compositions have been found to show 
effective taste masking abilities with improved flavor such as alkaline earth oxide, alkaline 
earth hydroxide or an alkaline hydroxide. Another composition includes phosphorylated 
amino acid such as phosphotyrosine, phosphoserine, and phosphothreonine and mixtures 
thereof.
  
Anethole effectively masked bitter taste as well as the after taste of zinc, which is 
used in treating the common cold. Clove  oil and calcium carbonate which has been found to 
be particularly useful to mask the unpalatable taste in formulation which are intended to be 
chewed or dissolved in mouth prior to ingestion. 
B) Applying Polymer Coatings 
  Coating of drugs using a suitable polymer offers an excellent method of 
concealing the drug from the taste buds. The coated composition may be incorporated into 
number of pharmaceutical formulations including chewable tablet, effervescent tablets 
powder and liquid dispersions.
 
Multiple encapsulated flavor delivery systems has been 
developed which is useful in chewing gum, pharmaceutical preparations as well as other food 
products. 
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12 
C) Complexation and Adsorption Approaches 
Complexation with ion exchange Resins and Polymers 
  Cat ion-exchange resin CRP 244 and anion exchange ion were used to adsorb 
ester drugs for both masking of bitter taste and achieving sustained release action. The types 
of ion exchange resins that have been successfully used to mask the taste of bitter drugs 
include amberlite IRP 88 (an acrylic potassium resin). amberlite IRP 64 (a polystyrene 
sulphonate) and amberlitr IRP 64 (a carboxylate form of the methapyrilene, 
dextromethrophan, ephedrine and pseudeuphedrine) were masked by first forming adsorbates 
with polymethacrylic acid ion exchange resin followed by coating of resin complex with 4:1 
mixture of ethyl cellulose and hydroxyl propyl methyl cellulose (HPMC) polymers. 
           Taste evaluation of the adsorbents showed a significant reduction in the 
bitterness of the drugs. Coating adsorbent particles with 3:1 ethyl cellulose – HPMC mixture 
reduced the bitterness further. Taste coverage was maintained after incorporation of the 
coated adsorbent in to chewable tablets. Strong acid cat ion resins ( sulfonated styrene 
divinyl benzene copolymer product) can be used for masking the taste of basic drugs.
23
 
Polystyrene matrix cat ion exchange resins have been used to mask the bitter taste of  
chlorpheniramine malate, ephedrine hydrochloride and diphenhydramine hydrochloride.
24
 
Extreme bitterness of quinolones has been achived by ion exchange resin such as methacrylic 
acid polymer cross linked with divinylbenzene. 
FORMULATION OF SYRUPS  
The major components of syrups are as follows: 
 Purified water 
 Sugar (sucrose) or sugar substitutes (artificial sweeteners). 
Traditionally syrups are composed of sucrose (usually between 60 and 80%) and purified 
water. Due to the inherent sweetness and moderately high viscosity of these systems, the 
addition of other  Sweetening agents and viscosity-modifying agents is not required. In 
addition, the high concentration of sucrose and associated unavailability of water (termed 
low water activity) ensures that the addition of  preservatives is not required. As the 
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13 
concentration of sucrose is reduced from the upper limit (e.g. through dilution), the addition 
of preservatives may be required. 
In some formulations, other non-sucrose bases may replace traditional syrup. One of the 
most popular is Sorbitol, which contains 64% w/w sorbitol , although other alternatives are 
available that are based on mixtures of sorbitol and glycerin. These non-sucrose bases may 
be mixed with traditional syrups, if required, in the formulation of oral syrups that possess a 
low concentration of sucrose in comparison to traditional syrups.  
More recently, many products have been formulated as medicated sugar-free syrups due to 
the glycogenetic and cariogenic properties of sucrose. For the afore-mentioned reasons, all 
medicinal products designed for administration to children and to diabetic patients must be 
sugar-free.  
Sugar free substitutes must therefore provide an equivalent sweetness, viscosity and 
preservation to the original syrups. To achieve these properties artificial sweeteners 
(typically saccharin sodium, aspartame), non-glycogenetic viscosity modifiers (e.g. 
methylcellulose, hydroxyethylcellulose) and preservatives (e.g. sodium benzoate, benzoic 
acid and parahydroxybenzoate esters) are included. 
                ■ Preservatives: Preservatives are not required in traditional syrups containing 
high concentrations of sucrose. Conversely, in sugar-free syrups, syrups in which sucrose has 
been substituted at least in part by polyhydric alcohol and in traditional syrups that contain 
lower concentrations of sucrose, the addition of preservatives is required.  
                 ■ Flavours: These are employed whenever the unpalatable taste of a therapeutic 
agent is apparent, even in the presence of the sweetening agents. The flavours may be of 
natural origin (e.g. peppermint, lemon, herbs and spices) and are available as oils, extracts, 
spirits or aqueous solutions. Alternatively, a wide range of synthetic flavours are available 
that offer advantages over their natural counterparts in terms of purity, availability, stability 
and solubility. Certain flavours are also associated with a (mild) therapeutic activity. For 
example, many antacids contain mint due to the carminative properties of this ingredient. 
Alternatively other flavours offer a taste-masking effect by eliciting a mild local anaesthetic 
effect on the taste receptors. Examples of flavours in this category include peppermint oil, 
chloroform and menthol. The concentration of flavour in oral syrups is that which is required 
to provide the required degree of taste-masking effectively. 
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                ■ Colours: These are generally natural or synthetic watersoluble, photo-stable 
ingredients that are selected according to the flavour of the preparation. For example, mint-
flavoured formulations are commonly green color, whereas in banana-flavored solutions a 
yellow colour is commonly employed. Such ingredients must not chemically or physically 
interact with the other components of the formulation. 
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2. AIM AND OBJECTIVE 
Aim of study: 
 To formulate  Ambroxol hydrochloride syrup by using different sweetening   
agents like sucrose , sucralose and sodium saccharin 
 To  evaluate  the various formulations and to select the ideal formulation.. 
 To perform  accelerated stability studies for all the formulations.                                                                 
 To compare the best formulation with  marketed tablet and syrup. 
PLAN OF WORK 
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3. PLAN OF WORK 
 The study was planned as follows 
 Literature survey 
 Preformulation study of drug  
 Preparation of different formulations. 
 Evaluation of  various  parameters such as 
1. pH 
2. Viscosity 
3. Specific gravity 
4. Assay 
5. Dissolution study 
6. Microbial testing  
7. Related substances 
 Stability testing of different formulations 
LITERATURE REVIEW 
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4. LITERATURE REVIEW 
Maheshwari R K et al.,
 6
 formulated the syrup  of poorly water-soluble drug Tinidazole. For 
the experiment, the blends containing solubilizers from the         category of hydrotropes, co 
solvents and water soluble solids were employed. The blends of randomly selected 
solubilizers were used for solubility studies. Based on the solubility studies, few blends 
showing largest solubilites were employed to make the syrup. This may reduce the individual 
concentration of solubilizers and so reduce their potential of toxicities. The formulated 
syrups were subjected to accelerated stability studies and they were found to be quite stable. 
Rajagopalan R et al.,
7
 formulated the syrup of poorly water-soluble drug    Paracetamol. For 
the experiment, the blends containing solubilizers from the category of hydrotropes, co 
solvents and water soluble solids were employed. The blends of randomly selected 
solubilizers were used for solubility studies. Based on the solubility studies, few blends 
showing largest solubilities were employed to make the syrup. This may reduce the 
individual concentration of solubilizers and so reduce their potential of toxicities. The 
formulated syrups were subjected to accelerated stability studies and they were found quite 
stable. 
Ferreira D C et al.,
8
 compared the stability of Ambroxol HCl  syrup without                       
sugar  prepared in their pharmacy with two commercial preparations containing sugar. The 
bottles were filled with 50ml of syrup containing  6mg/ml Ambroxol HCl. The bottles were 
stored at 40ºC, 50ºC and 60ºC. Before filling and immediately after filling and at intervals 
during 75 days of storage, samples were taken and analysed by HPLC for Ambroxol HCl. 
The prediction of their syrup formulation shelf life was carried out by the accelerated 
stability programme. 
Abdelkawy M et al.,
9
 developed three simple, reliable methods for  the simultaneous 
determination of Ambroxol HCl and Guaifenesin in the presence of oxidative degradants. 
The three methods used were isocratic HPLC method, TLC-spectrodensitometric method and 
multivariate spectrophotometric method. The methods were applied for pharmaceutical 
dosage forms containing either ambroxol alone (drops, capsules)and ambroxol together with 
guaifenesin syrup   They have concluded that Multivariate calibration method was better 
method when compared to others for syrup dosage form due to interfering additives. 
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Stephen childs
10
 presented a review on maple syrup. In the review he has given about 
crystallization, how to control crystallization and crystallization inhibitors, invert sugar, 
advantages, Maillard reaction etc., 
Patel Divyakant A et al.,
11
 formulated and evaluated herbal syrup from the leaves of 
Neolamarckia cadamba (Roxb.) Bosser and  have concluded that the syrup they have 
developed has unique position in development of new formulations. 
Khan hajera et al.,
12
 Developed and validated a dissolution test for Gemifloxacin mesylate 
and Ambroxol hydrochloride tablets using spectrophotometric method. The established 
dissolution conditions were: 900ml of 0.01M Hcl (pH2.0) as dissolution medium, using 
paddle apparatus at a stirring rate of 50rpm. The drug release was evaluated by UV 
spectrophotometric method at 271nm for Gemifloxacin mesylate and 243.5nm for Ambroxol 
hydrochloride. The method was validated to meet requirements for a global regulatory filing 
which includes linearity, specificity, precision, accuracy, robustness and ruggedness. 
Joseph H B et al.,
13
Prepared syrups from orange juice serum and were tested for stability 
against microbial and chemical degradation. Syrups containing 70% soluble solids did not 
support growth of osmophilic yeasts, while pure sugar syrups prepared at 70ºBrix maintained 
cultures of yeasts for 35 days at 30ºC. Therefore orange syrups appear to contain microbial 
inhibitors. Nonenzymic browning of orange syrups was measured at 30ºC. Browning rates 
were lower when syrups were measured at 30ºC. Browning rates were lower when syrups 
were prepared from serum treated with cation exchange resin to remove amino acids and 
lower pH. Browning rates were higher when syrups were prepared from this serum after the 
pH was adjusted to 4.5. 
Abdul A S et al.,
14
 developed Ambroxol pellets to present in the form of capsules (Modified 
release capsules). Ambroxol coated pellets were formulated by using commercially available 
pellets and the capsules were filled by capsule filling machine. The accelerated stability 
studies were done  for one month. They have concluded that the developed formulation has 
minimum volume in size, greater surface area and more surface disintegration time for pellets 
in capsules. Small volumes of pellets enter into the systemic circulation very fast. Moreover 
no accumulation of drug in the body occurs 
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Mizanur R M et al.,
15
 prepared Ambroxol HCl sustained release matrix tablets by response 
surface methodology. 2
3
 factorial design was used for the preparation of tablets. They have 
concluded that optimization of Ambroxol HCl by Response Surface Methodology is quite 
efficient. 
Brooks A A et al.,
16
 Examined five different types of high sugar paediatric syrups for 
bacteriological status. A second line investigation was also conducted on samples which did 
not show any sign of bacterial growth during the first trial. All the products gave low counts 
of contaminating bacteria when they were diluted directly, plated out on conventional solid 
media and colonies counted. Higher counts were obtained when the cells were reactivated 
and plated on hypertonic mannitol salt agar. They have concluded that the presence of some 
bacteria is indicative of unwholesome products which may have serious health implications 
in neonates and children. 
Priya c Jain et al.,
17
 formulated taste masking Ambroxol Hydrochloride microspheres using 
spray drying technique using HPMC and PVP. The percentage yield was found to be 28.23% 
and the encapsulation efficiency was found to be 50.8%. the in-vitro drug release was found 
to be 70.39% in 0.1N HCl and pH 6.8 phosphate buffer solution. 
Anbu Jeba Sunilson J et al.,
18
 formulated and evaluated polyherbal cough syrup.The 
aqueous ethanol extracts of various traditional herbs like Adhatoda vasica, Acorus calamus, 
Glyzyrrhiza glabra, Ocimum sanctum, Tylophora asthmatica, Piper longum and Solanum 
xanthocarpum was evaluated for its antihistaminic activity by the inhibition of histamine 
induced contractions on the guinea pig ileum. The results showed that the formulated cough 
syrup inhibited histamine induced contractions of guinea pig ileum at 2.5 to 25 μg/ml 
concentrations in a dose dependent manner (p < 0.01, p < 0.05) and also significantly (p < 
0.05) inhibited degranulation of mast cells. All the results were well comparable with the 
standard benadryl cough syrup (diphenhydramine). 
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DRUG PROFILE  
AMBROXOL HYDROCHLORIDE
 [18]
 
 
Molecular formula : C13 H18 Br 2 N2O.HCL 
Chemical name : Trans4-2 anino-3, 5 dibromo benzyl amino Cyclohexanol hydrochloride 
Appearance  : A white or almost white crystalline powder odorless or almost odorless. 
Solubility  : soluble in methanol 
  N, N –dimethyl formanide 
  Slightly soluble in water and ethanol 
  Practically insoluble in chloroform and benzene  
Storage  : ambroxo hydrochloride should be protected from light. 
Therapeutic category:
 
Expectorant: enhanced mucolytic 
Respiratory disorders:
 
*Used in a variety of respiratory disorders including chronic 
   bronchit  
* Cystic fibrosis and infant respiratory distress syndrome .Also used in 
t  the treatment of cough. 
Uricosuric action : It also shows uricosuric effect. The minimum effective does of  
lowering plasma uricacid concentrations was found to be between 
250 mg and 500 mg daily given in 2 divided doses. Although these 
doeses are much higher than those used to treat broncho pulmonary 
disease, doses as high as 1 gram daily were well tolerated. 
Daily dose : 30 to 120 mg has been given by mouth in 2 to 3 divided doses. 
Adverse effect : hyper sensitivity a report of contact allergy to Ambroxol. 
Mechanism of action    : Ambroxol hydrochloride is a potent mucolytic and mucokinetic 
 capable of inducing bronchial  secretion. It is particularly useful in it  
mucus plugs are present. 
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Pharmacokinetics  
Ambroxol hydrochloride is rapidly absorbed from the gastrointestinal tract and under goes 
extensive first pass metabolism in the liver .It is widely distributed to body tissues .About 
85% of the drug is excreted as metabolites .It is highly bound to plasma proteins. It has a 
terminal half life of about 12 hours.  
Ambroxol hydrochloride crosses the blood brain barrier and small amounts cross the 
placenta. Administration of Ambroxol hydrochloride by mouth to healthy subjects produce 
peak plasma concentration after about 1hour .Only small amounts were excreted unchanged 
in the urine with a half –life of about 6.5 hours. 
Precautions
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It is advisable to avoid use during the first trimester of pregnancy. 
Ambroxol Dosage 
Adults  : Daily dose of 30 mg (one Ambroxol tablet )to 120 mg (4 
    Ambroxol tablets) taken in 2 to 3 divided doses. 
Children up to 2 years  : Half teaspoonful Ambroxol syrup twice daily 
Children 2 - 5 years  : Half teaspoonful Ambroxol syrup 3 times daily 
Children over 5 years  : One teaspoonful Ambroxol syrup 2-3 times daily. 
Storage : Store at a temperature not exceeding 30 degrees celsius. 
 Keep all medicines out of reach of children.  
Ambroxol Indications 
All forms of tracheobronchitis, emphysema with bronchitis pneumoconiosis, chronic 
inflammatory pulmonary conditions, bronchiectasis, bronchitis with bronchospasm 
asthma. During acute exacerbations of bronchitis it should be given with the 
appropriate antibiotic. 
 Ambroxol Contraindications 
There are no absolute contraindications but in patients with gastric  
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Brand Names: Mucosolvan and Mucoangin 
Ambroxol is used for infections of the upper respiratory tract. It clears airways 
and eases cough. It enhances pulmonary surfactant production and stimulates ciliary 
activity. These actions result in improved mucus flow and transport (mucociliary 
clearance). Improvement of mucociliary clearance has been shown in clinical 
pharmacologic studies. Enhancement of fluid secretion and mucociliary clearance 
facilitates expectoration and eases cough. 
Pregnancy and Lactation 
Preclinical studies as well as extensive clinical experience after the 28th week 
have shown no evidence of ill-effects during pregnancy. Nonetheless, the usual 
precautions regarding the use of drugs during pregnancy, especially during the first 
trimester, should be observed. The drug enters breast milk, but is not likely to affect 
the infant when therapeutic doses are used. 
    Side Effects 
Mucosolvan is generally well tolerated. Mild upper gastro-intestinal side 
effects (primarily pyrosis, dyspepsia, and occasionally nausea, vomiting) have been 
reported, principally following parenteral administration. Allergic reactions have 
occurred rarely, primarily skin rashes. There have been extremely rare case reports of 
severe acute anaphylactic-type reactions but their relationship to ambroxol is 
uncertain. Some of these patients have also shown allergic reactions to other 
substances. 
Overdosage  
No symptoms of overdosage have been reported in man to date. If they occur, 
symptomatic treatment should be provided.  Administration of ambroxol together with 
antibiotics (amoxicilline, cefuroxime, erythromycin, doxycycline) leads to higher antibiotic 
concentration in the lung tissue. No clinically relevant unfavorable interaction with other 
medications have been reported.  
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Glycerin 
 
Nonproprietary Names 
 BP    :  Glycerol 
 JP    :   Concentrated glycerin 
 PhEur   :  Glycerolum 
 USP    :   Glycerin 
Synonyms  : Croderol; E422; glycerine; Glycon G-  
100; Kemstrene; Optim; Pricerine; 1,2,3-  
propanetriol; trihydroxypropane glycerol. 
Chemical Name   : Propane-1,2,3-triol 
Empirical Formula    : C3H8O3 
Molecular Weight      : 92.09 
Functional Category   :  Antimicrobial preservative; emollient;   
                                                               Humectants; plasticizer; solvent; 
                                                               Sweetening agent; tonicity agent. 
TYPICAL PROPERTIES   
Boiling point   :  290ºC (with decomposition) 
Density   :  1.2656 g/cm
3
 at 15ºC  
Melting point  :  17.8ºC 
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SOLUBILITY TABLE : 
Table no: 2 Solubility of glycerin. 
Solvent Solubility at 20ºC 
Acetone Slightly soluble 
Benzene Practically insoluble 
Chloroform     Practically insoluble 
Ethanol (95%)     Soluble 
Ether 1 in 500 
Ethyl acetate     1 in 11 
Methanol     Soluble 
Oils Practically insoluble 
Water Soluble 
VISCOSITY OF GLYCERIN: 
Concentration of aqueous 
glycerin solution (% w/w)   
Viscosity at 208C (mPas) 
 
5 1.143 
10 1.113 
25      2.095 
50      6.05 
60   10.96 
70       22.94 
83       111.0 
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Table no: 3 viscosity of glycerin 
SPECIFIC GRAVITY OF GLYCERIN: 
Table no: 4 specific gravity of glycerin 
Concentration of aqueous 
Gl ycerin solution (% w/w) 
Specific gravity at 
20
0
C 
10 1.024 
20 1.049 
30 1.075 
40 1.101 
50 1.128 
60 1.156 
STABILITY & STORAGE  
Condition : Glycerin is a stable  hygroscopic material.The  bulk material should be 
stored in a well closed container in cool and dry place. 
Applications : In oral solutions, glycerin is used as a solvent, sweetening agent, 
antimicrobial preservative and viscosity-increasing agent. It is also 
used as a plasticizer and in film coatings Glycerin is additionally used in 
topical formulations such as creams and emulsions. 
PROPYLENE GLYCOL 
Structure formula  
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Nonproprietary names  
 BP                     :  Propylene glycol 
 JP                   :  Propylene glycol 
 PhEur              :  Propylenglycolum 
 USP                  :   Propylene glycol 
Synonyms                         :
 
1,2-Dihydroxy propane ; 2-hydroxy propanol;         
                                                  methyl glycol ;propane-1,2-diol  
Chemical name      : 1,2-propanediol. 
Empirical Formula        :
  
C3H8O2 
Molecular weight         : 76.09 
Structural formula        :
  
CH3CHOHCH2OH  
Functional Categor : Antimicrobial preservative, disinfectant, stabilizer for 
vitamins, humectants water miscible co-solvent, 
plasticizer. 
Description        :        Clear, colorless, viscous, partially colorless liquid with 
   a sweet, slightly acrid taste resembling glycerin. 
TYPICAL PROPERTIES 
Density   :  1.038 g/cm3 at 50ºC 
Boiling point   :  188
0
 C 
Viscosity   :  58.1 mPs at 50
0
C  
Solubility  :  Miscible with acetone, chloroform, ethanol (95%) glycerin,   
water. Soluble 1 in 6 parts of ether. Not miscible with light  
mineral oil, Dissolves in some essential oils. 
Incompaillties   :  It is incompatible with oxidizing reagents such as 
             potassium permanganate. 
Applications   : It is widely used as a solvent, extractant, preservative in a 
                                                 variety of parenteral and non parenteral preparation. 
                                                  Propylene glycol is commonly used as a plasticizer in  
                                                 aqueous film coating formulation. 
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SUCRALOSE 
Structure formula  
                         
Nonproprietary names  
USPNF     : Sucralose 
Synonyms                          : 1,4,6-trichlorogalactosucrose; 4,1,6-trichloro-4,1,6-    
                                                  trideoxy-galacto-sucrose. 
chemical name  : 1,6-Dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-  
  deoxy-α-H-galactopyranoside. 
Empirical Formula        : C12H19Cl3O8 
Molecular weight         : 397.64 
Functional Category        : Sweetening agent. 
Description        : Sucralose is a white to off-white colored, free-flowing, 
                                                  Crystalline powder. 
TYPICAL PROPERTIES 
Density        : 0.35 g/cm3 
Melting point        : 130
0
C 
Viscosity        : 0.6-3.8 mPas 
Solubility                   : Freely soluble in ethanol (95%), methanol, and water; 
                                                  slightly soluble in ethyl acetate. 
Stability and Storage       : Sucralose should be stored in a well-closed container in a  
Conditions    : cool and dry place. 
Applications       : Sucralose is used as a sweetening agent in beverages,     
                                                  foods, and pharmaceutical applications.  It has a sweetening  
                                                  power approximately 300–1000 times that of sucrose and  
                                                  has no aftertaste. It has no nutritional value. 
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SACCHARIN SODIUM 
 Structural formula 
                                      
Nonproprietary names 
 BP    :  Saccharin Sodium 
 JP    :   Saccharin Sodium 
 PhEur   : Saccharinum natricum 
 USPNF   :  Saccharin Sodium 
Synonyms   : 1,2-Benzisothiazolin-3-one 1,1-dioxide,    
Sodium salt; Crystalose; E954; sodium  
o-benzosulfimide; soluble gluside; soluble 
saccharin; sucaryl sodium.  
Chemical Name    : 1,2-Benzisothiazol-3(2H)-one1,1-dioxide,  
      sodium salt. 
Empirical Formula     : C7H4NNaO3S 
Molecular weight       : 205.16 
Functional category   :  Sweetening agent. 
Typical properties   :  
Density    :  0.8-1.1 g/cm
3
  
Melting point    : Decomposes upon heating. 
Stability & Storage Condition :          Saccharin sodium is stable under the normal  
                range of conditions employed in formulations. 
               Saccharin sodium should be stored in a well 
                closed container in a cool , dry place. 
Applications                            : Saccharin sodium is an intense sweetining agent 
used in beverages,  food products, table-top 
sweeteners, and pharmaceutical formulations such 
as tablets, powders, Medicated confectionery, gels, 
suspensions, liquids, and mouthwashes. 
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SUCROSE
[23]
 
Structural formula  :  
                       
Nonproprietary names  
 BP                   :   sucrose 
 JP                    :  sucrose 
 PhEur             :  saccharum 
 USPNF          :   sucrose 
Synonyms  :    Beet sugar,cane sugar,-α-D-glucopyranosyl-β-D-fructofuranoside. 
Chemical name          :           β-D-fructofuranosyl-α-D-glucopyranoside 
Empirical formula     :            C12H22O11. 
Molecular weight :  342.30 
Functional category :  Coating agent, granulating agent, suspending agent, 
                                                 sweetening agent, tablet binder. 
Description  :  Sucrose is a sugar obtained from sucrose occurs as  
                                                  colorless crystals or as a white crystalline powder. It is  
                                                  odorless and has a sweet taste. 
Typical properties 
Density :      0.93g/cm3 
Melting point :   160-186
o
c 
Stability and storage :      Sucrose has good stability at room         
conditions                        temperature. The bulk material should be stored in a well closed 
container in a cool,dry place. 
Applications :        Sucrose is widely used in oral pharmaceutical formulations. 
Sucrose syrup containing 50-60% - w/w sucrose, it is used in 
tableting as a binding agent for wet granulation. 
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HYDROXYPROPYL CELLULOSE 
Structural formula 
                                       
Nonproprietary names 
 BP    :  Hydroxypropyl cellulose 
 JP    :   Hydroxypropyl cellulose  
 PhEur   :  Hydroxypropyl cellulosum 
 USPNF   :  Hydroxypropyl cellulose 
Synonyms    : Cellulose, hydroxypropyl ether ; E463;  
      Hyprolose; Klucel; Methocel;Nisso HPC;  
      oxypropylated cellulose.    
Chemical Name    : Cellulose,2-hydroxypropyl ether 
Molecular weight       : 50,000-1,250,000 
Functional category    :  coating agent; emulsifying agent; stabilizing 
agent; suspending agent; tablet binder;         
thickening agent; viscosity-increasing agent. 
Typical properties     
Density   :  0.5 g/cm
3
  
Melting point   : 260-2750 C. 
Stability & Storage Condition : Hydroxypropyl cellulose powder is a stable  
material, it was hygroscopic after drying. 
Hydroxypropyl cellulose powder Stored in a 
well closed container in a cool, dry place.  
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Incompatibilities :     Hydroxypropyl cellulose in solution 
demonstrates such incompatibility with 
substituted phenol  derivatives, Such as 
methylparaben and propylparaben. The presence 
of anionic polymers increase the viscosity  
hydroxypropyl cellulose solutions. 
Applications   : Concenration of 15-35% w/w of hydroxypropyl 
cellulose may be used to produce tablets with an 
extended drug release. Aqueous solutions 
containing hydroxypropyl cellulose along with 
an amount of methyl cellulose or ethanoic 
solutions may be used. 
MENTHOL 
Structural formula:  
                                        
Nonproprietary names         : 
 BP                  : Racementhol 
 JP                   :            Menthol 
 phEur              : Mentholum racemicum 
 Usp                 : Menthol 
Synonyms    :      Hexahydrothymol,2-isopropyl-5- methycyclohexanol,4- 
                   iso-propyl-1-methylcyclohexan -3-ol;3-p-menthanol. 
Chemical name  :  C10H20O  
Molecular weight  :  156.27 
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 Specific gravity :  0.890 at 15°C  
 Refractive index :  1,458 at 25°C  
 Melting point  : l-Menthol 43-44°C; the USP allows a melting  
                                                 range of 41°-44°C racemic menthol displays a  
                                               congealing point at two levels: 27-28°C and 30.5-32°C  
 Boiling point  :  212°C  
 Flash point  :  200°F/93°C  
 Solubility  :  H2O at 20°C = 0.04%; soluble in ethanol,  
     essential oils, esters, alcohols, chlorinated  
     solvents, mineral and edible oils etc.  
  Application    :  Menthol is widely used in pharmaceuticals  
      confectionery, and toiletry products as a flavoring  
 agent or odor enhancer. It is also used in orul syrups and 
inhalation,oral  suspension,tablets and topical 
formulations. 
SODIUM CITRATE DIHYDRATE
[23]
 
 Structure formula  
    
Nonproprietary Names                                      
 BP                             :         sodium citrate  
 Jp                              :         sodium citrate 
 Usp                           :          sodium citrate  
 Pheur                        :          natrii citras         
Synonyms                                    :        citric acid trisodium salt; SODIUM citrate  
        tertiary , trisodium citrate. 
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Chemical name                           :        Trisodium  2-Hydroxypropane-1,2,3- tricarboxyylate 
dehydrate. 
Empirical formula                    :      C6H5NA3O7.2H2O 
Molecular weight                    :      294.10 
Functional category                   :      Alkalizing agent, buffering agent, emulsifier, 
sequestering agent. 
Description                                   :        sodium citrate dihydrate consists of odorless,  
          colorless, a white crystalline powder. 
Typical properties                         
                   Density                        :       1.12g/cm 
                   Melting point              :       150
o 
C 
Stability and storage conditions : Sodium citrate dehydrate is a stable material. Aqueous 
solutions may be sterilized by autoclaving. On storage, 
aqueous solutions may cause the separation of small, 
solid particles from glass containers. 
Incompatibilities                           : Aqueous solutions are slightly alkaline and will react 
with acidic substance. Alkaloidal salts may be 
precipitated from their aqueous or hydro-alcoholic 
solutions .Calcium and strontium salts will cause 
precipitation of the corresponding citrates. Other 
incompatibilities include bases, reducing agents, and 
oxidizing agents. 
Application                             :         It is used in food product. Adjust the pH of  solution.it 
is also used as a sequestering agent.the anhydrous 
material is used in effervescent tablet formulations.                                                                                                                                                  
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7. MATERIALS AND METHODS 
7.1 Materials used in the study: 
Table no. 5 List of materials used: 
S.no : Name of the 
materials 
Manufacturer /supplier Function 
01 Ambroxol HCL  koraer inida-koraesina Active ingredient 
02 Sucrose Dharani sugar pvt.ltd.T.N Sweetner  
03 Sodium saccharin China pvt-ltd vardhaman & 
co.chennai 
Sweetner 
04 Sucralose  Tate&lyte Pvt-ltd KP manis 
global co.chennai  
Sweetner 
05 Propylene glycol 
I.P 
Salicylate pvt-ltd chemicals 
Hyderabad 
 Preservative  
06 Glycerin  Godroj industries Ltd. Mumbai Viscosity builder 
07 Hydroxypropyl 
cellulose 
Laffano detro chemicals ltd. 
Gujarat. 
Viscosity builder 
08 Menthol Hindustan Pvt-ltd  vardhaman 
co Chennai. 
Flavouring  agent  
09 Citric acid   Sunil chemical  Acidulate  
10 Sodium citrate  Sunil chemical Buffering agent  
11 Flavouring oil  Aromatics India pvt ltd Daman. Flavouring agent 
 
MATERIALS AND METHODS 
35 
7.2Equipments used in the study: 
Table no: 6 List of instruments /equipments used: 
s.no Instrument /Equipments Manufacture/supplier 
01. Electronic waghing balance Shimadzu Japan. 
02. Viscometer Lab equipement MMC pvt ltd. Chennai. 
03. pHmeter Digisun electronics Hyderabad. 
04. Dissolution test apparatus Veego (UDA-60) 
05. U.V Visible spectrophotometer UV pharma spec 1700 Shimadzu 
06. HPLC HPLC - LC 99 Shimadzu, Japan. 
07. TLC Lab equipement MMC pvt ltd. Chennai. 
08. Water bath Lab equipement  MMC pvt ltd Chennai. 
09. Humidity chamber 
Lab equipement  MMC pvt ltd 
Chennai. 
10 Hot air oven Lab equipement  MMC pvt ltd Chennai. 
11 Melting point Lab equipement  MMC pvt ltd Chennai. 
12 FTIR Lab equipement  MMC pvt ltd Chennai 
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7.3 PREFORMULATION STUDIES OF AMBROXOL HYDROCHLORIDE 
 It is one of the important prerequisite in development of any drug delivery system. 
Pre formulation studies were performed on the drug, which included melting point 
determination, solubility and compatibility studies. 
7.3.1 Determination of melting point:
[24] 
 Melting point of Ambroxol HCl was determined by capillary method. Fine powder of 
Ambroxol hydrochloride was filled in glass capillary tube (previously sealed on one end). The 
capillary tube is tied to thermometer and the thermometer was placed in flam. The powder at 
what temperature it will melt was noticed. 
 
7.3.2 Solubility:
 
 
  1mg Ambroxol HCl was dissolved in 100ml of different solvents like water 
methylene chloride, ethanol and ether separately and was tested for solubility as per BP 2000. 
 7.3.3 Determination of λmax:
 
                           A solution of Ambroxol HCl containing the concentration 10 µg/ ml was prepared 
in 0.1N HCl and UV spectrum was taken using Shimadzu UV double beam spectrophotometer. 
The solution was scanned in the range of 200 to 400 nm.  
7.3.4 Preparation of standard stock solution of ambroxol hydrochloride 
 30mg of ambroxol hydrochloride was dissolved in 100ml of 0.1N HCl. Aliquot of 
stock solution was further diluted by using the same solvent to obtain concentration range from 
80mcg/ml- 120mcg/ml. The absorbance of the solutions was measured at 301nm using UV-
visible spectrophotometer. 
7.3.4.1 Preparation of 0.1N Hydrochloric acid
 
             8.5ml of the hydrochloric acid was taken and dissolved in water and made upto  
1000ml to get 0.1N hydrochloric acid. 
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Drug excipient compatibility study
[25] 
Compatibility studies were carried out to study the possible interactions 
between Ambroxol hydrochloride and other inactive ingredients. The compatibility 
studies were carried out with an aim to select a suitable excipient for a stable and best 
formulation. A blend of drug with the excipient in suitable ratios were filled in glass 
vials for exposing to 40
0
C/75% RH and observed for physical changes. 
Procedure: 
APl and excipients were thoroughly mixed in predetermined ratio given in table 
below and the blend was filled in white colored glass vials and closed with gray rubber 
stoppers and sealed with aluminum seal and charged in to condition at 40
0 
C/75 %RH. 
Similarly API was also kept  per the sample. 
Table no : 7 Compostion of drug and excipients used for Compatibility study  
S.no Composition details Ratio 
01 Drug  1 
02 Drug +sodium saccharin 1:0.5 
03 Drug+ menthol 1:0.1 
04 Drug + hydroxypropyl cellulose 1:0.3 
05 Drug + sucrose 1:2 
06 Drug+ sucrolose 1:05 
Chemical compatibility of the above samples was verified using FTIR spectrums. 
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Testing frequency: 
1. Once a month for 3 months for sample charged at 400C/75%RH. 
2. 7.3.6.1 Physical Observation: 
3. Physical observation of sample was done at every week for any colour change 
or lumps formation and flow. 
4. Drug excipients compatibility studies: 
7.3.5 Compatibility studies by FTIR:
[26], [27] 
Ambroxol HCl with polymers was subjected to IR studies Infrared (IR) spectroscopy 
was conducted using a FTIR Spectrophotometer and the spectrum was recorded in the 
wavelength region of 4000 to 400 cm
−1
. The procedure consisted of dispersing a sample (drug 
alone and excipients) in KBr in the ratio of 100:1 and compressed into discs by applying a 
pressure of 5 tons for 5 min in a hydraulic press. The pellet was placed in the light path and the 
spectrum was obtained with principle peaks. The peaks obtained by IR spectroscopy are 
compared with drug standard IR spectra. 
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7.4 FORMULATION DEVELOPMENT 
Following ingredients were selected to develop the desired formulation  
Table no: 8 Composition used in the formulation of syrups: 
Ingredients(g) S-1 S-2 S-3 S-4 S-5 
Ambroxol Hcl (g) 3 3 3 3 3 
Propylene glycol(g) 50 100 150 50 50 
Glycerin(g) 50 100 150 50 50 
Sucralose(g) 1.5 1.5 1.5 - - 
Sodium saccharin(g) - - - 1 - 
Sucrose (g) - - - - 250 
HPC (g) 1 1 1 1 1 
Menthol (g) 0.5 0.5 0.5 0.5 0.5 
Critic acid(g) 1 1 1 1 1 
Sodium citrate(g) 1 1 1 1 1 
DM Water qs Make up  500 ml Make up  500 ml Make up  500 ml Make up  500 ml Make up  500 ml 
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Procedure: 
Step: I  
       Propylene glycol was mixed with the active pharmaceutical ingredient Ambroxol 
hydrochloride. 
Step: II 
     To the above mixture hydroxypropyl cellulose and glycerin   were added and mixed well 
using 100 ml of water. 
Step: III 
     The resultant mixture was stored in a well closed container for 20 hours or over night at 
room temperature. 
Step: IV 
     0.5 ml of flavoring agent was then added and the pH
 
was measured. 
STEP: V 
     The pH
 
was adjusted to pH
 
4.5by using citric acid solution and sodium citrate solution. 
Step: VI 
     After 20 hrs or over night storage sucralose or sucrose or saccharin sodium was added and 
the volume was made upto 500 ml using distilled water. 
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7.5 EVALVATION OF SYRUP 
7.5.1 pH 
[28] 
            pH is  defined as the negative logarithm of hydrogen ion concentration. 
Mathematically it is written as  
pH = log 1/[H3o
+
] 
Since the logarithm of 1 is zero 
The evolution may also be written 
pH= 
_
 log[H3o
+
] 
Determination of pH 
pH of syrup was determined by using pH meter. pH of the syrup also contributes to stability 
and characteristics of formulations. So  pH of the syrup was recorded from time to time. 
7.5.2 SPECIFIC GRAVITY
[28] 
The clean and dry empty specific bottle was weighed. Then the bottle was completely filled 
with distilled water and weighed. After cleaning and drying, the bottle was filled completely 
with the liquid whose specific gravity was to be determined and was weighed. 
Observation:  
                       Weight of empty dry specific gravity bottle  = W1g 
                       Weight of specific gravity bottle filled with water =W2g 
                       Weight of specific gravity bottle filled with liquid =W3g 
Calculation : 
                       Mass of water = W2 – W1 g 
                       Mass of liquid = W3  - W1 g 
Specific gravity =   mass of liquid/mass of equal volume of water =W3-W1/W2-W1 
7.5.3 VISCOSITY:
[29] 
      Viscometer was thoroughly cleaned with a mixture of warm chromic acid. It was then 
filled with distilled water and clamped vertically onto a stand. The viscosity of the liquid to be 
determined is delivered from a pipette into the limb with bulb E. The quantity of liquid should 
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be such that, when it is sucked through the tube in the next limb, the upper level stands above 
the A mark and the lower level stands in the other limb at the bottom of bulb E. First, the 
distilled water was sucked until its upper meniscus in above A, its level marked and allowed 
to flow down. The stop clock was started when it reaches A mark and stopped when the level 
reaches B mark. The flow time was noted down in seconds in the tabular column. The 
procedure was repeated till the agreement values are obtained. The viscometer was cleaned 
again and equal volume of liquid was taken and the flow time was determined in second as 
above. The density of the liquid with specific gravity bottle was determined and viscosity was 
calculated 
Time in seconds flow x viscometer factor x wt/ml of water x wt/ml of liquid. 
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7.6 MICICROBIAL EXAMINATION:
[30] 
PROCEDURE:  
7.6.1 TOTAL BACTERIAL COUNT:
 
Preparation of media 
      Soyabean casein digest broth medium 
      Pancreatic digest of casein                  17.0g 
     Papain digest of soya bean                3.0g 
Sodium chloride                                     5.0g 
      Dipotassium hydrogen phosphate          2.5g 
      Dextrose monohydrate                           2.5g 
      Water to                                                1000ml 
Adjust the pH so that after sterilization it is 7.3±0.2.Sterilise. 
Sample preparation: 
     1ml of sample was collected, using sterile pipettes. It was then transferred to 10ml of 
soyabean casein digest broth medium. 
Procedure: 
    1ml of the sample was pipetted out into two separate sterilized petridishes.15ml of the 
soyabean casein digest agar medium (SCDA) in petridish, was added at not more than 45
o
C. 
Sample was mixed with media by slightly shaking the plates for uniform mixing of the sample 
and allowed to solidify. Incubate at 30-35
o
C for 3 days. A negative control is also prepared in 
the same manner for comparison. 
7.6.2 TOTAL FUNGAL COUNT:
 
 
Preparation of media 
Sabouraud chloramphenicol agar medium (SCA) 
       Peptones (meat and casein)                   10.0g 
       Dextrose monohydrate                          40.0g 
       Agar                                                       15.0g 
       Water to                                               1000 ml 
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Adjust the pH so that after sterilisation it is 5.6 ± 0.2 sterilise. Immediately before use, 
add 0.1 g of benzylpenicillin sodium and 0.1 g of tetracycline or alternatively add 50 mg of 
chloramphenical  per litre of medium as sterile solution. 
Sample Preparation: 
1ml of the sample was collected, using sterile pipettes. It was transferred to 10ml of 
Sabouraud chloramphenicol agar medium (SCA). 
Procedure: 
1ml of the sample was pipetted out into two separate sterilized petridishes, 15ml of the 
Sabouraud chloramphenicol agar medium (SCA) in petridish was poured, at not more than 
45˚C. Sample was mixed with media by slightly shaking the plates for uniform mixing of the 
sample and allowed to solidify. It was then incubated at 20-25˚C for 5 days. A negative 
control is also prepared in the same manner for comparison. 
INTERPRETATION OF RESULTS: 
      For Total bacterial count: 
CFU /ml  = Average CFU obtained on SCDA plates x 10 
 (10 is dilution factor) 
If no microbial colonies observed from the incubated petriplates   express  the   
results as < 10 CFU /g of sample. 
            
For Total Fungal count: 
       CFU / ml  = Average CFU obtained on SCA plates x 10 
       (10 is dilution factor) 
       If no microbial colonies observed from the incubated petriplates   express the results  
       as < 10 CFU /g of sample. 
Acceptance criteria: 
Total Bacterial count:  100 CFU/ml 
Total Fungal count:        10 CFU /ml 
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7.6.3 TEST FOR PATHOGENS 
7.6.3.1 For E.coli: 
Preparation of media: 
      Mac-Conkey broth 
Pancreatic digest of gelatin    20.0 g 
Lactose      10.0 g 
Dehydrated ox bile     5.0   g 
Bromocersol purple     10 mg 
Water  to                 1000 ml 
     Adjust the pH so that after sterilization it is 7.3 ± 0.2. Sterilize. 
Procedure: 
1ml of the above prepared sample was transferred to 100ml of Mac-Conkey broth and 
incubated at 30-35˚C for 24-48 hrs. 
7.6.3.2 For Salmonella:
 
 
Preparation of media 
      Soyabean casein digest broth medium 
      Pancreatic digest of casein                  17.0g 
      Papain digest of soya bean                   3.0g 
      Sodium chloride                                    5.0g 
      Dipotassium hydrogen phosphate         2.5g 
      Dextrose monohydrate                          2.5g 
      Water to                                              1000ml 
Adjust the pH so that after sterilization it is 7.3±0.2.Sterilise. 
     Rappaport Vassiliadis Salmonella enrichment broth 
Soya peptone                                    4.5g 
Sodium chloride                                         7.2g 
Potassium dihydrogen phosphate               1.26g 
Di-potassium hydrogen phosphate              0.18g 
Magnesium chloride (anhydrous)                13.58 
Malachite green                                            0.036g 
Adjust the pH to 5.2±0.2 at 25ºC 
MATERIALS AND METHODS 
46 
Directions: 
Suspended 26.75g in 1 litre of distilled water and heated gently to diisolve. 10ml of the 
above was dispensed into screw-capped bottles or tubes and sterilised by autoclaving at 115ºC 
for 15 min. 
     Xylose- Lysine- Desoxycholate agar 
Xylose                                   3.5g 
L-Lysine                                5.0g 
Lactose                                  7.5g 
Sucrose                                  7.5g 
Sodium chloride                    5.0g 
Yeast extract                         3.0g 
Phenol red                            80mg 
Agar                                     13.5g 
Sodium desoxycholate         2.5g 
Sodium thiosulphate            6.8g 
Ferric ammonium citrate       800mg 
Water to                                     1000ml 
Directions: 
     Adjusted the pH to 7.4±0.2. heated just to boiling and cooled to 50ºC and poured into petri 
dishes. 
Sample preparation: 
10 ml of the sample was transferred to 100 ml of soyabean casein digest broth and 
incubated at 30-35
0 
C for 18-24 hrs. From this 0.1ml of the sample was tranferred to a test 
tube containing Rappaport Vassiliadis Salmonella enrichment broth and incubated at 30-35ºC 
for 24-48hrs. It was then subcultured on a plate of xylose lysine deoxycholate agar and 
incubated at 30-35ºC for 24-48 hrs. 
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7.6.3.3 For Pseudomonas:
 
 
Preparation of media: 
Cetrimide agar media:  
     Pancreatic digest of gelatin                 20g 
     Magnesium chloride                               1.4g 
     Potassium sulphate                                  10g 
     Cetrimide                                              0.3g 
     Agar                                                    13.6g 
     Glycerin                                       10.0g 
     Water to                                               1000ml 
Directions: 
     Heated for 1min with shaking and the pH was adjusted to 7-7.4 and sterilized. 
Sample preparation: 
     The prepared sample was subcultered on a plate of cetrimide agar and incubated at 30-
35ºC for 18-72hrs. 
7.6.3.4 For Staphylococcus:
 
 
Mannitol salt agar medium: 
Pancreatic digest of casein                            5.0g 
Peptic digest of animal tissue                           5.0g 
Beef extract                                                       1.0g 
D-Mannitol                                                        10.0g 
Sodium chloride                                              75.0g 
Agar                                                                   15.0g 
Phenol red                                                           25mg 
Water to                                                              1000ml 
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Directions: 
 The above mixture was mixed well and heated with frequent agitation and boiled for 1 min to 
effect the solution. After sterilization the pH was adjusted to 7.4±0.2. 
Sample preparation: 
     The sample preparation was subcultured on a plate of Mannitol salt agar (MSA) and 
incubated at 30-35ºC for 18-72hrs 
Acceptance criteria: Pathogens:Should be absent 
.ASSAY 
Accurately measured 10 ml of syrup was transferred to a 100 ml volumetric flask. Volume 
was made up with 0.1 N HCl. From the above 5ml of the solution was withdrawn and made 
upto 50ml with 0.1 N HCl and sonicated for 30 min .The absorbance of the resulting solution 
was measured at 308 nm.  
7.7 RELATED SUBSTANCES 
Determination by liquid chromatography. 
Test solution: 
     Dissolve 50 mg of the substance under examination in water and dilute to 50 ml with the 
same solvent. 
Reference solution (a). 
      Dissolve 5 mg of ambroxol hydrochloride RS in 250 ml of water. Dilute 5 ml of the 
solution to 100 ml with the mobile phase. 
Reference solution (b).   
     Dissolve 5 mg the substance under examination in 0.2 ml of methanol and add 0.04 ml of a 
mixture of 1 volume of formaldehyde solution and 99 volumes of water. Heat at 60
0
C for 
5minutes. Evaporate to dryness under a current of nitrogen .Dissolve the residue in 5 ml of 
water and dilute to 20 ml with the mobile phase. 
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Chromatographic system. 
     A stainless steel column 25 cm x 4mm, packed with octadecylsilane bonded to porous 
silica. 
Mobile phase : a mixture of equal volumes of acetonitrile and a buffer solution prepared by 
dissolving 1.32 g of ammonium phosphate in 9000 ml of water , adjusting the pH to 7.0 with 
phosphoric acid and diluting to 1000 ml with water 
Flow rate .1 ml per minute 
Spectrophotometer set: at 254 nm, 
A 20µl loop injector. 
Inject reference solution (b).The test is not valid unless the resolution between the 
secondary peak (trans-4-6,8-dibromo-1,4-dihydroquinazolin-3(2H)-yl)cyclohexanol) and the 
Ambroxol peak is at least 4.0. 
Inject the test solution and reference solution (a). Continue the chromatography for 3 
times the retention time of the principal peak in the chromatogram obtained with the test 
solution. The area of any secondary peak in the chromatogram obtained with the test solution 
is not more than 5 times the area of the principal  peak in the chromatogram obtained with 
reference solution(a)(0.5 percent).The sum of the areas of all the secondary peaks is not more 
than 10 times the area of the principal peak in the chromatogram obtained with reference 
solution (a)(1.0 percent).Ignore any peak with an area 0.1 times the area of the principal peak 
in the chromatogram obtained with reference solution (a)(0.01 percent). 
7.8 DISSOLUTION STUDY:
[31] 
5ml of Ambroxol HCl syrup was taken and the in-vitro drug release was studied using 
USP (type II) paddle apparatus with a speed at 50rmp. Dissolution was tested in acidic 
medium (0.1N HCl) of 900 ml at 37± 0.5
0
C. Samples were withdrawn at 15, 30, 45 and 60min 
and filtered through 0.45 µ membrane filter and the absorbance of the resulting solution was 
measured at 308 nm using U.V visible spectrophotometer after suitable dilution. 
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7.9 STABILITY TESTING 
STABILITY STUDIES OF THE FINISHED PRODUCT.
[32] 
 Stability of a drug can be defined as the time from date of manufacture and packaging 
of the formulation until its chemical or biological activity is not less than a predetermined 
level of labeled potency and its physical characteristics have not changed appreciably or 
deleteriously. Although there are exceptions 90% of labeled potency is recognized as the 
minimum acceptable potency level. 
 The international conference on harmonization (ICH) guideline titled. “Stability 
testing of new drug substance and products (QIA)” describes the stability test requirements. 
ICH specifies the length of study and storage conduction. 
 Accelerated testing 400C± 20C/75% RH±5% and 30 + 2ºC/65+5%RH for 6months. 
Stability studies for the present work was carried out at 40
0 
C± 2
0
C 175% RH for the 
selected formulation for three months. 
Method: 
     The selected formulations were packed in wide mouthed bottle. They were stored at 
40º±2ºC/75±5%RH for 3 months in humidity chamber and evaluated for their physical 
appearance and various parameters at specified intervals of time. 
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8. RESULTS AND DISCUSSION 
 
8.1 Preformulation study of Ambroxol HCl 
8.1.1 Melting point determination:  
Melting point of Ambroxol HCl was found to be 237ºC. 
8.1.2  Solubility:  
Table No: 9 Solubility of Ambroxol HCl in various solvents  
Sr. No.  Solvents Solubility 
1 Water Sparingly soluble 
2 Methylene chloride Slightly soluble 
4 Ethanol Soluble 
6 Ether Practically insoluble 
 
8.1.3 Determination of λmax:  
From the UV spectrum of drug, it was concluded that the drug had λmax of 308 nm 
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8.1.4 Standard calibration curve of Ambroxol HCL  : 
Table No: 10 Absorbance data for the calibration curve of Ambroxol HCl in 0.1N HCl 
S. No Concentration (µg/ml) Absorbance 
1 0 0 
2 60 0.254 
3 80 0.338 
4 100 0.422 
5 120 0.505 
6 140 0.596 
 
 
                 Fig No: 1 Standard calibration curve of Ambroxol HCL in 0.1N HCl 
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8.2 Drug excipient compatibility study 
 
Table no: 11 Physical incompatibility study of API and excipients 
S.no Composition details Ratio 
STROAGE 40
0
C/75%RH. 
30
th 
day 
01 Drug 1 NCC 
02 Drug +sodium saccharin 1:0.5 NCC 
03 Drug+ sucrose 1:0.1 NCC 
04 Drug+sucrolose 1:0.3 NCC 
05 Drug + hydroxypropyl cellulose 1:2 NCC 
06 Drug + menthol 1:05 NCC 
 
 
8.1.5 Compatibility studies by FTIR: 
Fig No: 2 FT-IR of Ambroxol HCl 
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Fig No: 3 FT-IR of Ambroxol HCl and Sodium saccharin 
 
Fig No: 4 FT-IR of Ambroxol HCl and Menthol 
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Fig No: 5 FT-IR of Ambroxol HCl and Hydroxypropyl cellulose 
 
 
Fig No: 6 FT-IR of Ambroxol HCl and Sucrose 
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Fig No: 7 FT-IR of Ambroxol HCl and Sucrolose 
 
 
         Table No: 12 FT-IR vibrations 
S. No. 
Type of 
Vibrations 
Range 
1 –NH2 1627 
   2      O – H 3387 
3      C – Br 500-650 
 
     The IR spectrum of Ambroxol HCL , Ambroxol HCL  and excipient were interpreted and 
identified. The chief absorption bands of the drug are present in the Ambroxol HCL  
excipients mixture with same degree of sharpness and position it indicates that there is an 
absence of physical and chemical interactions among both active component and the excipient. 
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8.3 Study of different parameters of formulations 
Table no: 13 Study of various parameters of different formulations 
Batches pH 
Specific 
gravity 
Viscosity Assay 
Total 
Viable 
Count 
S1 4.51 1.12 5.09 109.74 
 
 
10 
S2 4.65 1.16 15.52 100.13 
 
 
10 
 
 
S3 4.72 1.18 30.44 102.97 
 
 
10 
S4 4.55 1.88 8.86 96.61 
 
 
10 
S5 4.57 1.18 26.98 99.12 
 
 
 
10 
 Pathogens, yeast and mould tests were completely negative. 
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7.7 RELATED SUBSTANCES 
 
Fig No: 8 HPLC of Test solution-Trial1 
 
 
 
 
 
 
Fig No: 9 HPLC of Test solution-Trial 2 
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Fig No: 10 HPLC of Test Solution-Trial 3 
 
 
 
 
Fig No: 11 HPLC of S1 formulation 
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Fig No: 12 HPLC of S2 formulation 
 
 
 
 
 
 
Fig No: 13 HPLC of S3 formulation 
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Fig No: 14 HPLC of S4 formulation 
 
 
 
 
 
 
Fig No: 15 HPLC of S5 formulation 
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7.8 DISSOLUTION STUDY 
 
Table No: 14 In-vitro drug release data for all formulations and marketed product 
 
SI 
.NO. 
TIME 
(MIN) 
CUMULATIVE % DRUG RELEASE 
S1 S2 S3 S4 S5 MARKET 
SAMPLE 
(SYRUP) 
MARKET 
SAMPLE 
(TABLET) 
1 15 105.03 86.32 84.07 86.32 86.04 84.07 58.11 
2 30 107.67 87.84 84.54 87.84 86.06 86.04 68.51 
3 45 111.37 89.36 88.04 88.04 88.37 86.06 80.08 
4 60 113.48 91.87 88.37 89.36 88.40 88.40 86.54 
 
 
 
Fig No: 16 In-vitro drug release profile for S1 formulation 
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Fig No: 17 In-vitro drug release profile for S2 formulation 
 
 
 
 
 
 
Fig No: 18 In-vitro drug release profile for S3 formulation 
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Fig No: 19 In-vitro drug release profile for S4 formulation 
 
 
 
 
 
 
Fig No: 20 In-vitro drug release profile for S5 formulation 
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Fig No: 21 In-vitro drug release profile for MSS formulation 
 
 
 
 
 
SIMILARITY FACTOR: 
 
   Comparison of the S1-S5 formulations with the innovator product was done by using the 
formulae given below: 
 
               f2 = 50Log {[1+1/n Wt Σn
t=1
 (Rt-Tt) 2] -0.5 ×100} 
 
Table No: 15 Similarity factor all formulations with MSS 
 
SI.NO Comparison f2 value 
1 MSS+S1 31.5 
2 MSS+S2 76.82 
3 MSS+S3 92.24 
4 MSS+S4 84.2 
5 MSS+S5 87.02 
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Fig No: 22 Comparison of In-vitro release profile of S3 and MSS 
 
 
 
 
 
 
 
Fig No: 23 Comparison of In-vitro release profile of S3 and MST 
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7.9 STABILITY TESTING 
Table No: 16 Stability studies of S1 formulation 
TEST 
  Specification 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Description 
Colourless flavoured clear 
syrupy liquid 
NCC NCC NCC 
 
NCC 
Identification 
Positive for the Ambroxol 
hydrochloride 
NCC NCC NCC 
 
NCC 
Recoverable 
Volume 
60ml 60ml 60ml 60ml 
 
60ml 
pH Lt: 4.0-4-5.0 4.51 4.67 4.72 
 
4.58 
Specific gravity Lt:1.10gm/ml-1.25 gm/ml 1.12 1.15 1.16 
 
1.12 
Viscosity  Lt:5mPas to 8mPas 5.99 7.36 7.38 
 
7.31 
Assay  Lt:90% - 110% 109.74 106.72 106.63 105.49 
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Table No: 17 Stability studies of S2 formulation 
 
TEST 
                                Specification 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Description 
Colourless flavoured 
clear syrupy liquid 
NCC NCC NCC NCC 
Identification 
Positive for the 
Ambroxol 
hydrochloride 
NCC NCC NCC NCC 
Recoverable 
Volume 
60ml 60ml 60ml 60ml 60ml 
P
H
 Lt: 4.0-4-5.0 4.65 4.72 4.59 4.78 
Specific gravity 
Lt:1.10gm/ml-1.25 
gm/ml 
1.16 1.16 1.13 1.17 
Viscosity  Lt:15mPas to 18mPas 15.52 15.95 15.23 16.10 
Assay  Lt:90% - 110% 100.13 97.12 97.78 97.09 
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Table No: 18 Stability studies of S3 formulation 
 
TEST 
                            Specification 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Description 
Colourless flavoured clear 
syrupy liquid 
NCC NCC NCC NCC 
Identification 
Positive for the Ambroxol 
Hcl 
NCC NCC NCC NCC 
Recoverable 
Volume 
60ml 60ml 60ml 60ml 60ml 
P
H
 Lt: 4.0-4-5.0 4.72 4.62 4.78 4.58 
Specific gravity Lt:1.10gm/ml-1.25 gm/ml 1.18 1.20 1.17 1.19 
Viscosity  Lt:30mPas to 33mPas 30.44 31.84 31.97 32.01 
Assay  Lt:90% - 110% 102.97 97.12 97.57 96.38 
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Table No: 19 Stability studies of S4 formulation 
 
TEST 
                              Specification 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Description 
Colourless flavoured clear 
syrupy liquid 
NCC NCC NCC NCC 
Identification 
Positive for the Ambroxol 
Hcl 
NCC NCC NCC NCC 
Recoverable 
Volume 
60ml 60ml 60ml 60ml 60ml 
P
H
 Lt: 4.0-4-5.0 4.55 4.78 4.82 4.76 
Specific gravity Lt:1.10gm/ml-1.25 gm/ml 1.18 1.20 1.16 1.17 
Viscosity  Lt:8mPas to 10mPas 8.86 9.45 9.59 9.43 
Assay  Lt:90% - 110% 96.61 93.22 90.11 87.73 
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Table No:20 Stability studies of S5 formulation 
 
TEST 
                         Specification 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Description 
Colourless flavoured 
clear syrupy liquid 
NCC NCC NCC NCC 
Identification 
Positive for the 
Ambroxol Hcl 
NCC NCC NCC NCC 
Recoverable 
Volume 
60ml 60ml 60ml 60ml 60ml 
P
H
 Lt: 4.0-4-5.0 4.57 4.76 4.83 4.78 
Specific 
gravity 
Lt:1.10gm/ml-1.25 
gm/ml 
1.18 1.12 1.16 1.15 
Viscosity  Lt:26mPas to 28mPas 26.98 26.82 27.40 27.46 
Assay  Lt:90% - 110% 99.12 96.68 96.40 95.68 
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Fig No: 24 HPLC of Test solution-Trial 1 after 1month of stability 
 
 
 
 
 
 
 
Fig No: 25 HPLC of Test solution-Trial 2 after 1month of stability 
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Fig No: 26 HPLC of Test solution-Trial 3 after 1month of stability 
 
 
 
 
 
 
 
 
Fig No: 27 HPLC of S1 after 1 month of stability 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
74 
 
Fig No: 28 HPLC of S2 after 1 month of  stability 
 
 
 
 
 
 
 
 
Fig No: 29 HPLC of S3 after 1 month of stability 
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Fig No: 30 HPLC of S4 after 1 month of stability 
 
 
 
 
 
 
 
Fig No: 31 HPLC of S5 after 1 month of stability 
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Fig No: 32 HPLC of Test solution-Trial 1after 2 month of stability 
 
 
 
 
 
 
 
Fig No: 33 HPLC of Test solution-Trial 2after 2 month of stability 
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Fig No: 34 HPLC of Test solution-Trial 3after 2 month of stability 
 
 
 
 
 
 
 
Fig No: 35 HPLC of S1 after 2 months of stability 
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 Fig No: 36 HPLC of S2 after 2 months of stability 
 
 
 
 
 
 
 
Fig No: 37 HPLC of S3 after 2 months of stability 
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Fig No: 38 HPLC of S4 after 2 months of stability 
 
 
 
 
 
 
 
 
Fig No: 39  HPLC of S5 after 2 months of stability 
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Fig No: 40 HPLC of Test solution-Trial 1 after 3 month of stability 
 
 
 
 
 
 
 
Fig No: 41 HPLC of Test solution-Trial 2 after 3 month of stability 
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Fig No: 42 HPLC of Test solution-Trial 3 after 3 month of stability 
 
 
 
 
 
 
 
 
Fig No: 43 HPLC of S1 after 3 month of stability 
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Fig No: 44 HPLC of S2 after 3 month of stability 
 
 
 
 
 
 
 
 
Fig No: 45 HPLC of S3 after 3 month of stability 
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Fig No: 46 HPLC of S4 after 3 month of stability 
 
 
 
 
 
 
 
 
Fig No: 47 HPLC of S5 after 3 month of stability 
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Table No: 21 Stability studies of S1 formulation - Microbial test 
 
TEST 
MICROBIAL TESTING 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Total viable count  100 CFU/ml 10 20 30 30 
Pathogens should be absent absent absent absent 
absent 
 
yeast and mould 
not more than 10 /CFU 
ml 
absent absent absent 
absent 
 
 
 
 
Table No: 22 Stability studies of S2 formulation - Microbial test 
 
TEST 
MICROBIAL TESTING 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Total viable count  100 CFU/ml 10 20 20 20 
Pathogens should be absent 
absent 
 
absent absent absent 
yeast and mould 
not more than 10 /CFU 
ml 
absent 
 
absent absent absent 
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Table No: 23 Stability studies of S3 formulation - Microbial test 
 
TEST 
MICROBIAL TESTING 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Total viable count  100 CFU/ml 10 20 20 20 
Pathogens should be absent 
absent 
 
absent absent absent 
yeast and mould not more than 10 /CFU ml 
absent 
 
absent absent absent 
 
 
 
Table No: 24 Stability studies of S4 formulation - Microbial test 
 
TEST 
MICROBIAL TESTING 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Total viable count  100 CFU/ml 10 20 30 40 
Pathogens should be absent absent absent absent 
absent 
 
yeast and mould not more than 10 /CFU ml absent absent absent 
absent 
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Table No: 25 Stability studies of S5 formulation - Microbial test 
 
TEST 
MICROBIAL TESTING 
STROAGE (IN MONTH) 
 
INITIAL 
1
ST 
MONTH 
2
nd
 
MONTH 
3
rd
 
MONTH 
Total viable count  100 CFU/ml 10 10 20 40 
Pathogens should be absent absent absent absent 
absent 
 
yeast and mould 
not more than 10 /CFU 
ml 
absent absent absent 
absent 
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DISCUSSION 
 Melting point of Ambroxol HCl was found to be 237ºC. 
Ambroxol was sparingly soluble in water, slightly soluble in methylene chloride and 
soluble in ethanol and practically insoluble in ether. 
 From the UV spectra of the drug it was confirmed that the drug is having maximum 
absorption at the wavelength of 308nm. 
It was found that the solutions of Ambroxol HCl in 0.1N HCl shows linearity (R
2
=0.998) 
in absorbance concentration of 60-140mcg/ml and obey’s Beer Lambert’s law. 
Syrups were formulated in different combinations as S1, S2, S3, S4 and S5 
Compatibility studies were done by FT-IR study and it was found that the excipients are 
compatible with the API. 
Different parameters like pH, specific gravity, Viscosity and assay were done for all the 
formulations and all the values were within the limit. 
The formulations were studied for the presence of microbes. All the values obtained were 
within the limit. Pathogenic organisms were absent. 
All the formulations were tested for related substances by HPLC method and no impurities 
was obtained during the study. 
From the release profile the similarity factor was calculated with the marketed syrup 
solution. The f2 value of S3 formulation was found to be higher (92.24) when compared to 
other formulations. 
All the formulations were kept for stability study and the parameters such as pH, specific 
gravity, Viscosity, Related substance and assay were found to be within the limit. 
10-30 bacterial colonies were formed in each formulations which was kept for stability 
study in accelerated condition and it was within the limit. 
There was no countable fungal colonies  observed in the accelerated conditions. 
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9. CONCLUSION 
 
From the study which was carried out it was concluded that: 
 
 The S3 batch was selected as the best formulation based on the various evaluation 
studies.  
 The formulation S3 was compared with a marketed sample of Ambroxol 
hydrochloride syrup and tablet and it was found that the drug release from the 
formulated syrup matches the drug release profile of the marketed syrup sample. The 
drug release from the formulated syrup was higher when compared with that of the 
marketed tablet sample. 
 Stability studies also concluded that the drug release profile or other parameters did 
not alter significantly after the accelerated stability studies. 
 Hence a stable ambroxol hydrochloride syrup which had a similarity factor of 93 with 
the marketed syrup was formulated successfully using sucralose as the sweetening 
agent. 
 Further work can be continued to make formulations with suitable excipients that can 
prevent crystallisation and to impart latest techniques to mask the bitter taste of the 
drug. 
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